Juan Pablo Castello1,2,3, Marco Pasi1,2,4, Patryk Kubiszewski1,2, Jessica R Abramson1,2,3, Andreas Charidimou1,2, Christina Kourkoulis1,2,3, Zora DiPucchio1,2, Kristin Schwab1,2, Christopher D Anderson1,2,3, M Edip Gurol1,2, Steven M Greenberg1,2, Jonathan Rosand1,2,3, Anand Viswanathan1,2, Alessandro Biffi1,2,3,5. 1. Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston. 2. Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston. 3. Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston. 4. Univ.Lille, Inserm, CHU Lille, U 1172 - LilNCog - Lille Neuroscience and Cognition, France (M.P.). 5. Department of Psychiatry (A.B.), Massachusetts General Hospital, Boston.
Abstract
BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is an acute manifestation of cerebral small vessel disease (CSVD), usually cerebral amyloid angiopathy or hypertensive arteriopathy. CSVD-related imaging findings are associated with increased depression incidence in the general population. Neuroimaging may, therefore, provide insight on depression risk among ICH survivors. We sought to determine whether CSVD CT and magnetic resonance imaging markers are associated with depression risk (before and after ICH), depression remission, and effectiveness of antidepressant treatment. METHODS: We analyzed data from the single-center longitudinal ICH study conducted at Massachusetts General Hospital. Participants underwent CT and magnetic resonance imaging imaging and were followed longitudinally. We extracted information for neuroimaging markers of CSVD subtype and severity. Outcomes of interest included pre-ICH depression, new-onset depression after ICH, resolution of depressive symptoms, and response to antidepressant treatment. RESULTS: We followed 612 ICH survivors for a median of 47.2 months. Multiple CSVD-related markers were associated with depression risk. Survivors of cerebral amyloid angiopathy-related lobar ICH were more likely to be diagnosed with depression before ICH (odds ratio, 1.68 [95% CI, 1.14-2.48]) and after ICH (sub-hazard ratio, 1.52 [95% CI, 1.12-2.07]), less likely to achieve remission of depressive symptoms (sub-hazard ratio, 0.69 [95% CI, 0.51-0.94]), and to benefit from antidepressant therapy (P=0.041). Cerebral amyloid angiopathy disease burden on magnetic resonance imaging was associated with depression incidence and treatment resistance (interaction P=0.037), whereas hypertensive arteriopathy disease burden was only associated with depression incidence after ICH. CONCLUSIONS: CSVD severity is associated with depression diagnosis, both before and after ICH. Cerebral amyloid angiopathy-related ICH survivors are more likely to experience depression (both before and after ICH) than patients diagnosed with hypertensive arteriopathy-related ICH, and more likely to report persistent depressive symptoms and display resistance to antidepressant treatment.
BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is an acute manifestation of cerebral small vessel disease (CSVD), usually cerebral amyloid angiopathy or hypertensive arteriopathy. CSVD-related imaging findings are associated with increased depression incidence in the general population. Neuroimaging may, therefore, provide insight on depression risk among ICH survivors. We sought to determine whether CSVD CT and magnetic resonance imaging markers are associated with depression risk (before and after ICH), depression remission, and effectiveness of antidepressant treatment. METHODS: We analyzed data from the single-center longitudinal ICH study conducted at Massachusetts General Hospital. Participants underwent CT and magnetic resonance imaging imaging and were followed longitudinally. We extracted information for neuroimaging markers of CSVD subtype and severity. Outcomes of interest included pre-ICH depression, new-onset depression after ICH, resolution of depressive symptoms, and response to antidepressant treatment. RESULTS: We followed 612 ICH survivors for a median of 47.2 months. Multiple CSVD-related markers were associated with depression risk. Survivors of cerebral amyloid angiopathy-related lobar ICH were more likely to be diagnosed with depression before ICH (odds ratio, 1.68 [95% CI, 1.14-2.48]) and after ICH (sub-hazard ratio, 1.52 [95% CI, 1.12-2.07]), less likely to achieve remission of depressive symptoms (sub-hazard ratio, 0.69 [95% CI, 0.51-0.94]), and to benefit from antidepressant therapy (P=0.041). Cerebral amyloid angiopathy disease burden on magnetic resonance imaging was associated with depression incidence and treatment resistance (interaction P=0.037), whereas hypertensive arteriopathy disease burden was only associated with depression incidence after ICH. CONCLUSIONS: CSVD severity is associated with depression diagnosis, both before and after ICH. Cerebral amyloid angiopathy-related ICH survivors are more likely to experience depression (both before and after ICH) than patients diagnosed with hypertensive arteriopathy-related ICH, and more likely to report persistent depressive symptoms and display resistance to antidepressant treatment.
Entities:
Keywords:
cerebral hemorrhage; depression; magnetic resonance imaging; siderosis; survivors; white matter
Authors: A M Grool; Y van der Graaf; W P Th M Mali; Th D Witkamp; K L Vincken; M I Geerlings Journal: Psychol Med Date: 2011-08-11 Impact factor: 7.723
Authors: Rocco J Cannistraro; Mohammed Badi; Benjamin H Eidelman; Dennis W Dickson; Erik H Middlebrooks; James F Meschia Journal: Neurology Date: 2019-05-29 Impact factor: 9.910
Authors: Andreas Charidimou; Sergi Martinez-Ramirez; Yael D Reijmer; Jamary Oliveira-Filho; Arne Lauer; Duangnapa Roongpiboonsopit; Matthew Frosch; Anastasia Vashkevich; Alison Ayres; Jonathan Rosand; Mahmut Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302
Authors: Steven M Greenberg; Brian J Bacskai; Mar Hernandez-Guillamon; Jeremy Pruzin; Reisa Sperling; Susanne J van Veluw Journal: Nat Rev Neurol Date: 2019-12-11 Impact factor: 42.937
Authors: Patryk Kubiszewski; Lansing Sugita; Christina Kourkoulis; Zora DiPucchio; Kristin Schwab; Christopher D Anderson; M Edip Gurol; Steven M Greenberg; Anand Viswanathan; Jonathan Rosand; Alessandro Biffi Journal: JAMA Neurol Date: 2020-08-31 Impact factor: 18.302
Authors: Sara N Rushia; Al Amira Safa Shehab; Jeffrey N Motter; Dakota A Egglefield; Sophie Schiff; Joel R Sneed; Ernst Garcon Journal: World J Radiol Date: 2020-05-28